Patient sample Questionnaire

Sudan University of Sciences and Technology

College of Graduate Studies

Questionnaire

No (    )

A-General Information:

- Name: ……………………………… - Age: (    ) years
- Gender: Male (    ) Female (    )
- Tribe: ………………………… - Residence: …………………

B-Clinical Information:

- Types of liver diseases:
  HCC (    ) HCV (    ) HBV (    ) Cirrhosis (    )

- Duration of disease:
  < 6mth (    ) 6mth-1yr (    ) 1yr-2 yr. (    ) > 2yr (    )

- Focal liver lesion: Yes (    ) No (    )

- Family history of HCC: Yes (    ) No (    )

- HCC:
  - Time of HCC detection:
    < 1yr (    ) 1-2 yr (    ) > 2 yr (    )
  - Size of HCC at AFP-L3 study:
    Undetectable (    ) < 2cm (    ) 2-5cm (    ) >5cm (    )
  - Number of lesion (    )
  - Location: Lt (    ) Rt (    ) both (    ) infiltrate (    )
  - Portal vein thrombosis: Yes (    ) No (    )
  - Diagnosis of HCC:
    Cytology (    ) Liver biopsy (    ) AFP (    )
    U/S: Contrast enhance (    ) CT scan (    ) MRI (    )
  - Liver biopsy: (Differentiation /grade)
    Differentiation: W.D (    ) M.D (    ) P.D (    ) unspecified (    )
    Grade: I (    ) II (    ) III (    ) IV (    )
Patient sample Questionnaire

- **Cirrhosis (based on U/S):**
  - Complications of Cirrhosis:
    - Edema and ascites ( )
    - Bruising and bleeding ( )
    - Toxins in the blood or brain ( )
    - Portal hypertension ( )
    - Jaundice ( )
    - Itching ( )
    - Gallstones ( )
    - Hepatic Encephalopathy ( )

**C-Laboratory Investigation:**

<table>
<thead>
<tr>
<th>Specimen</th>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum</td>
<td>AFP-L3</td>
<td>- ......ng/ml (0-4 ng/ml)</td>
</tr>
<tr>
<td></td>
<td>T.AFP</td>
<td>- .....IU/ml (1-10 IU/mL)</td>
</tr>
<tr>
<td>plasma</td>
<td>LFT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Protien. Total</td>
<td>- ...... g/dL (6 to 8 g/dL)</td>
</tr>
<tr>
<td></td>
<td>- Albumin</td>
<td>- .......g/dl (3.5 to 5.5 g/dL)</td>
</tr>
<tr>
<td></td>
<td>- ALT</td>
<td>- ......IU/L (9 to 40 IU/L)</td>
</tr>
<tr>
<td></td>
<td>- AST</td>
<td>- ......IU/L (10 to 35 IU/L)</td>
</tr>
<tr>
<td></td>
<td>- ALP</td>
<td>- ......IU/L (30 to 120 IU/L)</td>
</tr>
<tr>
<td></td>
<td>- Total BIL</td>
<td>- ....mg/dl (0.2–1.2 mg/dL)</td>
</tr>
<tr>
<td></td>
<td>- Direct BIL</td>
<td>- ....mg/dl (0.1–0.4 mg/dL)</td>
</tr>
<tr>
<td></td>
<td>- Indirect BIL</td>
<td>- ......up to 0.8</td>
</tr>
<tr>
<td></td>
<td>- GGT</td>
<td>- ......IU/L (0 to 42 IU/L)</td>
</tr>
<tr>
<td></td>
<td>- INR</td>
<td>- ........</td>
</tr>
<tr>
<td></td>
<td>- PT</td>
<td>- ......</td>
</tr>
</tbody>
</table>

Date: ........................ Signature: ........................